Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Mabgeek Biotechnology

Request full access

Maiji Biopharma, the first domestic company to list, leads globally in independent R&D and clinical trials of innovative antibodies

ChinaFounded 2016Biotech & Life Sciences

About Mabgeek Biotechnology

Hunan Mabgeek Biotechnology Co., Ltd. is a clinical-stage biopharmaceutical company established in 2016 by founder Dr. Zhang Chenghai. The firm concentrates on the independent research, development, and commercialization of antibody drugs to address unmet clinical needs in allergic inflammatory and autoimmune diseases. Dr. Zhang Chenghai has a background in overseeing the research and clinical application of numerous antibody drugs, bringing extensive experience to the company's focus. Mabgeek Biotechnology operates in the drug discovery industry, specifically targeting the immuno-inflammation field.

The company's business model is centered on the development and subsequent commercialization of a pipeline of innovative antibody drugs. A key asset is the proprietary TEADA antibody discovery platform, which is designed to efficiently screen for candidate molecules with high biological activity and favorable drug-like properties. Mabgeek has entered into strategic collaborations to advance its pipeline, such as a partnership with Chime Biologics for manufacturing and development, and another with China Medical System for co-development and commercialization rights of its lead product in several Asian territories. In August 2025, the company filed for an Initial Public Offering (IPO) in Hong Kong to secure funding for its development pipeline.

Mabgeek's primary product candidate is MG-K10, a long-acting monoclonal antibody that targets the IL-4Rα receptor. This antibody is designed to simultaneously block two key cytokines, IL-4 and IL-13, which are involved in type 2 inflammatory diseases. A significant feature of MG-K10 is its extended half-life, allowing for a less frequent dosing schedule of once every four weeks, compared to the current standard of every two weeks for similar treatments. The drug is currently in Phase III clinical trials for moderate-to-severe atopic dermatitis and asthma. The company's pipeline also includes other antibody candidates in various stages of development, such as anti-TSLP (Phase I), anti-IL-33, and anti-MASP-2 mAb, for conditions in dermatology, respiratory, and nephrology.

Source: Dealroom company data

At a glance

Status
Operational
Open positions
None listed
Dealroom signal
21.0/100
Industry
Health
Sub-industry
BioTechnology
Sector
Biotechnology, Research and Development, Biotech and Pharma, DT and LS, science-based
Business model
Manufacturing
Client focus
B2B
Links
Website

Funding history

2 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
LATE VC✓Equity / VC Jul 2025 $14M $363M Undisclosed ↗
SERIES B✓Equity / VC Aug 2024 $28M $138M Undisclosed ↗
Showing the latest 2 of 2 recorded eventsBook a demo for the full funding history →

Growth signals

Mabgeek Biotechnology website traffic

Latest recorded traffic for Mabgeek Biotechnology is 2.2K monthly website visits, up 22.2% over the last three months.

Latest monthly visits2.2K 3-month web change+22.2%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Mabgeek Biotechnology in its local ecosystem

Live from Dealroom

The Mabgeek Biotechnology office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Founders Hidden — book a demo/100 quality score
Key operators Hidden — book a demo quality score
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
🇨🇳 China HQ
Book a demo for the full country breakdown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Mabgeek Biotechnology on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Mabgeek Biotechnology’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.